Covid-19: Regulatory Obstacles to U.S. Recovery

James R. Copland joins Brian Anderson to discuss how America's uniquely cumbersome regulatory system impeded the national response to the Covid-19 crisis and how costly litigation could damage the economy even further. The FDA and CDC's administrative failings in the early days of the crisis proved costly. The federal process for reviewing and approving drugs and medical devices, writes Copland, still leaves much to be desired. And a wave of coronavirus-related lawsuits poses a serious threat to future business viability.